Vascularized composite allotransplantation (VCA)

Vascularized composite allotransplantation (VCA) is the transplantation of a body part composed of multiple tissue types, typically including skin, subcutaneous fat, muscle, bone, cartilage, nerves, and blood vessels, recovered and transplanted as a single functional anatomical unit that requires surgical reconnection of blood vessels to restore blood flow [1][2]. Unlike conventional solid organ transplants such as the kidney or liver, a VCA replaces a complex composite structure (for example a hand or a face) rather than a single organ, and it is generally performed to restore form and function rather than to save the recipient's life [1][3]. The best-known forms of VCA are hand and upper-extremity transplantation and face transplantation, although the category also includes abdominal-wall, uterus, penis, and larynx transplants [1][2]. In the United States, VCA was formally brought under federal organ-transplant oversight in 2014, when it was added to the Organ Procurement and Transplantation Network (OPTN) definition of an "organ" [2][4].

Definition and defining characteristics

A VCA is distinguished by its composite makeup: a single graft contains several distinct tissue types of differing antigenicity arranged as a structural unit [1][2]. To be classified as a VCA under the OPTN Final Rule, a body part must meet a set of criteria, including that it is (1) vascularized and requires surgical connection of blood vessels to function after transplantation; (2) composed of multiple tissue types; (3) recovered from a human donor as an anatomical or structural unit; (4) transplanted into a human recipient as an anatomical or structural unit; (5) minimally manipulated; (6) intended for homologous use; (7) not combined with a device; (8) susceptible to ischemia and therefore stored only temporarily, not cryopreserved; and (9) susceptible to allograft rejection, generally requiring immunosuppression that may increase the recipient's risk [2][4]. This last characteristic, susceptibility to rejection requiring immunosuppression, is central to how VCA is regulated and to the ethical analysis of the procedure [2][3].

Regulatory framework in the United States

Before 2014, the OPTN Final Rule (codified at 42 CFR part 121, implementing the National Organ Transplant Act (NOTA)) defined a covered "organ" as a human kidney, liver, heart, lung, pancreas, or intestine [4]. On July 3, 2014, an amendment to the rule took effect that added VCAs to the regulatory definition of "organ," thereby placing VCA recovery, allocation, and transplantation under OPTN oversight on the same legal footing as solid organ transplantation [2][4]. The change had been issued as a final rule published in the Federal Register on July 3, 2013, with a one-year effective date of July 3, 2014 [2][4].

Bringing VCA under the OPTN meant that VCA transplant programs became subject to the same federal framework that governs solid organ programs, including program approval and membership requirements, standardized protocols, candidate listing procedures, quality-control obligations, and mandatory submission of donor, recipient, and outcomes data to the OPTN [1][2]. The OPTN recognizes several VCA categories for oversight purposes, broadly grouped as upper limb; head and neck (including face, larynx, scalp, and trachea); abdominal wall; genitourinary organs (including uterus and penis); glands; lower limb; musculoskeletal composite tissue; and spleen [1].

Examples of VCA

VCA encompasses a growing range of procedures [1][2]:

• Hand and upper-extremity transplantation, the most established peripheral VCA, in which a hand or part of the arm is transplanted from a deceased donor. Approximately 151 upper-extremity transplants had been performed worldwide as of December 2024, including about 38 in the United States [1]. See hand transplantation.
• Face transplantation, ranging from partial to near-total facial allografts. About 53 face transplants had been performed worldwide as of December 2024, including roughly 20 in the United States [1]. See face transplantation.
• Abdominal-wall transplantation, often performed together with intestinal or multivisceral transplantation to achieve abdominal closure; roughly 46 had been performed globally over about two decades [1].
• Uterus transplantation, which is unique among VCAs in that it is most often performed from living donors and is intended to be temporary, with the graft removed after one or more pregnancies are completed. It has become one of the most frequently performed VCA types in the United States [1][5].
• Penile (genitourinary) transplantation, of which only a small number had been performed worldwide [1].
• Laryngeal transplantation, a rare procedure with a small number of reported cases [1].

Immunology and rejection monitoring

The central immunological challenge of VCA is that the skin component of the graft is highly antigenic, making composite allografts more prone to acute rejection than many solid organs [3][6]. Acute rejection is common: studies have reported acute rejection in at least 85% of hand-transplant recipients within the first year and in the large majority of face-transplant recipients [1][3]. Because the skin is both the most antigenic and the most accessible component, it serves as the principal target for rejection surveillance, which is performed largely through serial skin biopsy supplemented by immunohistochemistry of the epidermis, dermis, vessels, and subcutaneous tissue [6][7].

To standardize how rejection is reported, an international consensus process produced the Banff 2007 Working Classification of Skin-Containing Composite Tissue Allograft Pathology, which grades acute skin rejection on a scale from 0 to 4 [6][8]:

• Grade 0: no or rare inflammatory infiltrates.
• Grade I (mild): mild perivascular infiltration without epidermal involvement.
• Grade II (moderate): moderate-to-severe perivascular inflammation with limited epidermal or adnexal involvement, without epidermal apoptosis.
• Grade III (severe): dense inflammation with epidermal involvement, including epithelial apoptosis, dyskeratosis, or keratinolysis.
• Grade IV (necrotizing): frank necrosis of the epidermis or other skin structures [8].

The Banff VCA classification has subsequently been revised and extended through later consensus meetings (for example, the Banff 2022 VCA meeting) to address additional findings such as antibody-mediated rejection, chronic changes, fibrosis, atrophy, and vascular changes that have been recognized as clinical experience has accumulated [6][9].

Immunosuppression and the risk-benefit calculus

VCA recipients require lifelong systemic immunosuppression, typically with multi-drug regimens, to control the heightened rejection risk associated with skin and vascularized composite tissue [3][6]. The associated risks include opportunistic infection, malignancy, kidney injury, diabetes, and other drug toxicities, the same categories of risk that accompany solid-organ immunosuppression [1][3]. The distinguishing feature of most VCA is that the transplant is restorative rather than life-saving: unlike a heart or liver transplant, a hand or face transplant does not avert imminent death, so the recipient accepts the lifelong risks of immunosuppression primarily for gains in function, appearance, and quality of life [1][3]. This altered risk-benefit balance is the core reason VCA is treated as ethically and clinically distinct from life-saving solid organ transplantation [2][3].

Donor authorization considerations

Donor authorization for VCA differs from authorization for solid organs in important ways [1][2]. Under OPTN policy, VCA recovery requires specific, separate authorization that is not assumed under a general first-person organ-donor registration or general family consent to organ donation; the organ procurement organization (OPO) must document that authorization for the particular VCA was obtained consistent with applicable state law [1][2]. These requirements reflect distinct psychological and practical considerations for donor families, including the visibility and identity associated with donating a face or hands, concerns about disfigurement and open-casket funeral arrangements, and the option of reconstructive or prosthetic restoration of the donor's body [1].

Surveys indicate these concerns affect willingness to donate. Reported public willingness to donate hands and faces declined between 2012 and 2019 (for example, willingness to donate hands fell from about 80% to 64% and faces from about 58% to 47%), and family authorization rates for hand and face donation were lower than for many solid organs [1]. A 2020 survey of OPO professionals also found that the workforce was largely inexperienced with VCA, with about 70% reporting they had never conducted a VCA donation discussion and about 75% reporting insufficient training [1].

Outcomes

Reported short- and medium-term outcomes for VCA have generally been favorable for the most established procedures, though numbers remain small and follow-up periods relatively short compared with solid organs [1][3]. In a retrospective analysis of OPTN data covering the first five years after the Final Rule, 36 VCA transplants were reported following the July 2014 rule change, comprising 16 uterus, 10 hand, and 6 face transplants [3]. Among 18 recipients of non-uterus VCA between July 3, 2014 and December 31, 2017, 17 (94%) were alive with a functioning graft as of March 2018 [3]. One of the 10 hand-transplant recipients (10%) had a reported graft loss, and uterus grafts failed in roughly one-quarter of cases in early U.S. experience, reflecting the distinct nature of uterus transplantation [3].

Broader international experience reported through December 2024 indicates that most U.S. face- and hand-transplant recipients have maintained functioning allografts, with reported five- and ten-year survival among an early cohort of about 50 face-transplant recipients of roughly 85% and 74%, respectively, and functional improvement after hand transplantation; a minority of grafts have required removal, and a small number of recipient deaths have been reported [1]. As of December 2024, VCA programs in the United States were concentrated at a limited number of approved centers (for example, on the order of ten approved head-and-neck sites and a comparable number of upper-limb sites), with uneven geographic distribution [1].

Ethics

The ethics of VCA center on the tension between substantial potential gains in quality of life and the burden of lifelong immunosuppression for a transplant that is not life-saving [1][3]. Commentators weigh the restorative and psychosocial benefits of regaining a hand, a face, or the ability to carry a pregnancy against the cumulative medical risks of chronic immunosuppression, the demanding rehabilitation involved, and the possibility of graft loss [1][3]. Additional ethical considerations include informed consent and candidate selection given the elective nature of the procedure, the distinct donor-family burdens and authorization requirements described above, equitable access given the small number of centers, and, for uterus transplantation, the involvement of living donors and the welfare of children born after transplantation [1][5]. These distinctive features are why VCA is governed by a separate authorization framework and is the subject of dedicated ethical and policy review even though it is regulated under the same statute as solid organ transplantation [2][3].

History

Attempts at composite-tissue transplantation long predated effective immunosuppression, but the modern era of VCA began in the late 1990s [1]. The world's first hand transplant was performed in Lyon, France, on September 23, 1998; the recipient, Clint Hallam, later stopped his immunosuppression, and the graft was amputated in 2001 [1][10]. The first hand transplant in the United States was performed in Louisville, Kentucky, in 1999 [1]. The first partial face transplant was performed in Amiens, France, in 2005, and the first U.S. face transplant was performed at the Cleveland Clinic in December 2008 on recipient Connie Culp, in a procedure led by surgeon Maria Siemionow [1][11]. The field expanded to additional anatomies in the following decade, and in November 2017 the first U.S. birth following a uterus transplant occurred at Baylor University Medical Center in Dallas [5][12]. The 2014 addition of VCA to the OPTN definition of "organ" marked the point at which these procedures came under unified federal transplant oversight in the United States [2][4].

See also

• Hand transplantation
• Face transplantation
• Organ transplantation
• Transplant immunology
• National Organ Transplant Act (NOTA)

References

• National Academies of Sciences, Engineering, and Medicine. "VCA Background Information and Context," in Advancing Face and Hand Transplantation (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK615569/
• OPTN / HRSA. Vascularized composite allotransplantation policy and OPO guidance on VCA deceased donor authorization. https://optn.transplant.hrsa.gov/professionals/by-topic/guidance/opo-guidance-on-vca-deceased-donor-authorization/
• Wainright JL, et al.. "Vascularized composite allotransplantation in the United States: A retrospective analysis of the Organ Procurement and Transplantation Network data after 5 years of the Final Rule," American Journal of Transplantation. https://www.amjtransplant.org/article/S1600-6135(22)08338-1/fulltext
• U.S. Department of Health and Human Services / HRSA. "Organ Procurement and Transplantation Network; Final Rule" (adding VCA to the definition of organ; 42 CFR part 121), Federal Register, July 3, 2013 (effective July 3, 2014). https://www.federalregister.gov/documents/2013/07/03/2013-15731/organ-procurement-and-transplantation-network
• Frontiers in Transplantation. "Uterus transplantation in the United States: analysis of patients and early postoperative outcomes in the national Organ Procurement and Transplantation Network." https://www.frontiersin.org/journals/transplantation/articles/10.3389/frtra.2026.1750905/full
• PubMed. "Vascularized composite allotransplantation: a closer look at the Banff working classification." https://pubmed.ncbi.nlm.nih.gov/26841362/
• PubMed. "Diagnosing skin rejection in vascularized composite allotransplantation: advances and challenges." https://pubmed.ncbi.nlm.nih.gov/24476538/
• ResearchGate / Cendales LC, et al.. "The Banff 2007 Working Classification of Skin-Containing Composite Tissue Allograft Pathology." https://www.researchgate.net/publication/5407355_The_Banff_2007_Working_Classification_of_Skin-Containing_Composite_Tissue_Allograft_Pathology
• American Journal of Transplantation. "Banff 2022 Vascularized Composite Allotransplantation Meeting Report: Diagnostic criteria for vascular changes." https://www.amjtransplant.org/article/S1600-6135(24)00064-9/fulltext
• Guinness World Records. "First hand transplant operation." https://www.guinnessworldrecords.com/world-records/first-hand-transplant-operation
• CBS News. "Connie Culp, who had first U.S. partial face transplant, has died at 57." https://www.cbsnews.com/news/connie-culp-dies-age-57-first-us-partial-face-transplant/
• Baylor Scott & White Health. "Baylor University Medical Center announces first baby born in U.S. from transplanted uterus." https://www.bswhealth.com/blog/baylor-university-medical-center-announces-first-baby-born-u-s-transplanted-uterus